OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Analysts' consensus: "Hold" — Five analysts cover OKYO (1 sell, 1 hold, 3 buy) with an average 12‑month target price of $6.33.
• Major earnings miss — OKYO reported Q EPS of ($2.28) versus consensus ($0.07), missing by $2.21, and sell‑side forecasts expect about (‑0.17) EPS for the current year.
• Shares are trading near $1.51 (down 4.4%), with a 50‑day/200‑day moving average of $1.72/$2.03 and a 12‑month range of $1.06–$3.35; institutional ownership is low at 2.97%, though Renaissance significantly increased its stake.

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have been given an average rating of "Hold" by the five analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $6.3333.

A number of research analysts recently issued reports on OKYO shares. Piper Sandler started coverage on OKYO Pharma in a report on Friday, February 20th. They issued an "overweight" rating and a $7.00 target price for the company. HC Wainwright reiterated a "buy" rating and issued a $7.00 target price on shares of OKYO Pharma in a report on Thursday, January 29th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of OKYO Pharma in a report on Thursday, January 22nd.

Institutional Trading of OKYO Pharma

A number of institutional investors have recently bought and sold shares of OKYO. Citadel Advisors LLC purchased a new stake in OKYO Pharma during the 3rd quarter worth about $31,000. Renaissance Technologies LLC increased its position in shares of OKYO Pharma by 235.0% during the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company's stock worth $286,000 after purchasing an additional 96,800 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of OKYO Pharma during the fourth quarter worth about $36,000. 2.97% of the stock is owned by hedge funds and other institutional investors.

OKYO Pharma Trading Down 4.4%

NASDAQ:OKYO opened at $1.51 on Friday. The stock has a fifty day moving average price of $1.72 and a 200 day moving average price of $2.03. OKYO Pharma has a 12-month low of $1.06 and a 12-month high of $3.35.

OKYO Pharma (NASDAQ:OKYO - Get Free Report) last released its earnings results on Friday, January 30th. The company reported ($2.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($2.21). As a group, sell-side analysts forecast that OKYO Pharma will post -0.17 earnings per share for the current year.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company's pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma's lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.